GlassScriptPhysician profile
Doris Hansen
NPI 1881958270
$141,342.83
in general payments reported to CMS, 2019-2025
20 companies · $62K in 2025
The $62K reported for 2025 was more than what 95% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2022: $9,985 · 2023: $19K · 2024: $50K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $88K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $19K · Food and Beverage: $2,823 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $87,741.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,049.00 |
| Travel and Lodging | $19,102.29 |
| Food and Beverage | $2,822.66 |
| Education | $173.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $37,055.89 | 2022-2025 | Abecma |
| Janssen Scientific Affairs, LLC | $26,245.87 | 2023-2024 | Carvykti, Tecvayli, Darzalex |
| Janssen Biotech, INC. | $20,223.04 | 2019-2025 | Carvykti, Rybrevant, Darzalex |
| Legend Biotech USA INC. | $19,902.39 | 2023-2025 | Carvykti |
| Celgene Corporation | $16,330.70 | 2022-2025 | Pomalyst, Abecma |
| Astrazeneca Pharmaceuticals LP | $5,044.54 | 2025 | Calquence |
| Astrazeneca Uk Limited | $4,980.00 | 2024-2025 | Calquence |
| Pfizer INC. | $4,634.45 | 2023-2024 | |
| Kite Pharma, INC. | $4,290.00 | 2025 | |
| Janssen Global Services, LLC | $1,897.65 | 2025 | Carvykti |
| Genzyme Corporation | $195.88 | 2019 | |
| Gilead Sciences, INC. | $189.31 | 2025 | |
| Novartis Pharmaceuticals Corporation | $100.12 | 2019 | |
| Astellas Pharma US INC | $95.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $68.21 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $39.30 | 2019 | |
| Abbvie INC. | $26.29 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $24.19 | 2025 | Lynozyfic |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.